SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08 févr. 2024 08h00 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics Announces Executive Leadership Change
02 févr. 2024 07h30 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
23 janv. 2024 17h58 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
02 janv. 2024 16h30 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human...
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
29 nov. 2023 07h30 HE
|
SAB Biotherapeutics, Inc.
First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG) SAB-142 directly and specifically targets multiple...
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
20 nov. 2023 07h30 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a...
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
14 nov. 2023 07h30 HE
|
SAB Biotherapeutics, Inc.
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditionsParticipating investors include Sessa Capital, BVF Partners, RTW...
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
14 nov. 2023 07h15 HE
|
SAB Biotherapeutics, Inc.
Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human Research Ethics Committee (HREC) to commence a...
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
09 nov. 2023 07h30 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
24 oct. 2023 07h30 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a...